← Leaderboards
Leopoldo Nicolas Segal
New York University School Of Medicine
$9,785,416
Attributed
$10,471,039
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,163,054 · 12
By mechanism
U2C$5,384,030 · 7
R37$4,060,246 · 1
R33$1,476,601 · 1
U01$1,028,435 · 1
K23$753,870 · 1
R21$459,872 · 1
Top collaborators
- Harvey Ira Pass3 shared
- Christian Forst2 shared
- Bin Zhang2 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Ivaylo Ivanov Ivanov$11,478,220
- Jill P Buyon$29,367,681
- Harvey Ira Pass$7,723,189
- Liat Shenhav$1,013,066
- Sergei Borisovich Koralov$6,368,246
Others in their field
Top investigators on “Investigation”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$681,473,477
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$448,008,305
- Judith S. Currier · University Of California Los Angeles$395,422,692
Research focus
InvestigationMicrobialSamplingTranscriptomeBlood SpecimenMortalityNon-Small-Cell Lung CarcinomaMicrobiomePathway InteractionsMalignant Neoplasm Of LungTranscriptomicsMultiple OmicsBloodCollaborationsBiological MarkersGrantEarly Detection Research NetworkCohortImmune ResponseMalignant NeoplasmsCellsMetabolomeMetabolomicsEvaluation
Grant awards (29)
Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancer$1,019,623
U2C · FY2025 · CA · contact PI
BIOREPOSITORY OPTIMIZATION AND USE FOR ENDOTYPING CRITICALLY ILL SARS-COV-2 INFECTED PATIENTS$732,923
R33 · FY2025 · GM · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$652,880
R37 · FY2025 · CA · contact PI
Age related loss of immune resilience during response to severe respiratory viral infections$500,424
U01 · FY2025 · AG · contact PI
Administrative Core$339,875
U2C · FY2025 · CA · contact PI
Biomarker Reference Lab$339,874
U2C · FY2025 · CA · contact PI
Biomarker Development Laboratory$339,874
U2C · FY2025 · CA · contact PI
Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancer$968,968
U2C · FY2024 · CA · contact PI
BIOREPOSITORY OPTIMIZATION AND USE FOR ENDOTYPING CRITICALLY ILL SARS-COV-2 INFECTED PATIENTS$743,678
R33 · FY2024 · GM · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$596,634
R37 · FY2024 · CA · contact PI
Age related loss of immune resilience during response to severe respiratory viral infections$528,011
U01 · FY2024 · AG · contact PI
Biomarker Development Laboratory$495,245
U2C · FY2024 · CA · contact PI
Administrative Core$388,276
U2C · FY2024 · CA · contact PI
Biomarker Reference Lab$85,447
U2C · FY2024 · CA · contact PI
Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancer$703,424
U2C · FY2023 · CA · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$626,640
R37 · FY2023 · CA · contact PI
Biomarker Development Laboratory$505,210
U2C · FY2023 · CA · contact PI
BIOREPOSITORY OPTIMIZATION AND USE FOR ENDOTYPING CRITICALLY ILL SARS-COV-2 INFECTED PATIENTS$207,405
R21 · FY2023 · GM · contact PI
Biomarker Reference Lab$102,447
U2C · FY2023 · CA · contact PI
Administrative Core$95,767
U2C · FY2023 · CA · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$652,794
R37 · FY2022 · CA · contact PI
BIOREPOSITORY OPTIMIZATION AND USE FOR ENDOTYPING CRITICALLY ILL SARS-COV-2 INFECTED PATIENTS$252,467
R21 · FY2022 · GM · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$665,878
R37 · FY2021 · CA · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$695,920
R37 · FY2020 · CA · contact PI
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer$169,500
R37 · FY2020 · CA · contact PI
Lung Microbiome and Inflammation in Early COPD$201,420
K23 · FY2017 · AI · contact PI
Lung Microbiome and Inflammation in Early COPD$184,150
K23 · FY2016 · AI · contact PI
Lung Microbiome and Inflammation in Early COPD$184,150
K23 · FY2015 · AI · contact PI
Lung Microbiome and Inflammation in Early COPD$184,150
K23 · FY2014 · AI · contact PI